BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 567 filers reported holding BIO-TECHNE CORP in Q4 2021. The put-call ratio across all filers is 0.60 and the average weighting 0.2%.
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 54,711 | $28,304,000 | 8.66% |
| Montanaro Asset Management Ltd | 104,450 | $54,036,000 | 5.45% |
| Ownership Capital B.V. | 891,186 | $461,046,000 | 4.99% |
| Sandhill Capital Partners LLC | 121,682 | $62,951,000 | 4.89% |
| Brown Capital Management | 986,803 | $510,513,000 | 4.22% |
| STONE RUN CAPITAL, LLC | 22,300 | $11,536,000 | 3.73% |
| DF DENT & CO INC | 681,416 | $352,524,000 | 3.54% |
| MAIRS & POWER INC | 653,815 | $338,244,000 | 3.13% |
| Summit Creek Advisors LLC | 57,959 | $29,985,000 | 3.01% |
| Aristotle Atlantic Partners, LLC | 95,597 | $49,456,000 | 2.87% |
| Pembroke Management, LTD | 74,363 | $38,471,000 | 2.82% |
| SANDLER CAPITAL MANAGEMENT | 61,930 | $32,039,000 | 2.77% |
| OBERMEYER WOOD INVESTMENT COUNSEL, LLLP | 99,239 | $51,340,000 | 2.75% |
| Jackson Square Partners, LLC | 601,329 | $311,091,000 | 2.62% |
| AMERICAN CAPITAL MANAGEMENT INC | 189,781 | $98,181,000 | 2.52% |
| GENEVA CAPITAL MANAGEMENT LLC | 258,427 | $133,694,000 | 2.16% |
| CROWN ADVISORS MANAGEMENT, INC. | 6,000 | $3,104,000 | 2.00% |
| Standard Family Office LLC | 411 | $213,000 | 1.89% |
| BAMCO INC /NY/ | 1,482,953 | $767,191,000 | 1.63% |
| ROWLANDMILLER & PARTNERS.ADV | 13,914 | $7,198,268,000 | 1.61% |
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
External links
This page lists BIO-TECHNE CORP's shareholders in Q4 2021. To view BIO-TECHNE CORP's shareholder history, click here.